Identifying potential combinatorial mechanism between paclitaxel and Almonertinib in lung cancer through multi-omics integration

Combination therapy using epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and cytotoxic chemotherapy is a promising strategy to overcome resistance in non-small cell lung cancer (NSCLC). However, the complicated molecular mechanisms remain elusive. Here, we employed an integrated multi-omics approach to dissect the molecular responses to the third-generation EGFR-TKI Almonertinib (Alm) and paclitaxel (PTX) and their combination in EGFR-mutant NSCLC cells. Transcriptomic and metabolomic profiling revealed that the combination therapy elicits an unique molecular signature distinct from either monotherapy alone. We identified a specific gene cluster (C8) that was suppressed only by the drug combination, and mainly enriched in cell cycle, DNA replication and mitochondrial function. The downregulation of these processes was validated in H1975 cells, and key genes (e.g., XRCC2 , SKA3 , TOMM40 ) also exhibited prognostic relevance. Meanwhile, metabolomic analysis uncovered a combination-specific blockade of mitochondrial fatty acid oxidation, evidenced by L-Carnitine depletion and accumulation of Hexanoyl-L-Carnitine and Oleoyl-L-Carnitine. This work demonstrates the potential combination interaction of Alm and PTX, converging on the suppression of cell cycle and the induction of carnitine metabolism blockage. Our findings provide a profound mechanistic rationale for this combination therapy.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2026-11-14
DOI
https://doi.org/10.1038/s41598-026-79550-7
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Identifying potential combinatorial mechanism between paclitaxel and Almonertinib in lung cancer through multi-omics integration

Tingze Feng, Shaojun Pei, Yiqian Wang, Ji-Wei Liu et al.
Scientific Reports
Lung Cancer Treatments and Mutations
article

Identifying potential combinatorial mechanism between paclitaxel and Almonertinib in lung cancer through multi-omics integration

Tingze Feng, Shaojun Pei, Yiqian Wang, Ji-Wei Liu, Di Chen, Jing Lv, Hailong Piao, Qiuping Wang
article en

Abstract

Combination therapy using epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and cytotoxic chemotherapy is a promising strategy to overcome resistance in non-small cell lung cancer (NSCLC). However, the complicated molecular mechanisms remain elusive. Here, we employed an integrated multi-omics approach to dissect the molecular responses to the third-generation EGFR-TKI Almonertinib (Alm) and paclitaxel (PTX) and their combination in EGFR-mutant NSCLC cells. Transcriptomic and metabolomic profiling revealed that the combination therapy elicits an unique molecular signature distinct from either monotherapy alone. We identified a specific gene cluster (C8) that was suppressed only by the drug combination, and mainly enriched in cell cycle, DNA replication and mitochondrial function. The downregulation of these processes was validated in H1975 cells, and key genes (e.g., XRCC2 , SKA3 , TOMM40 ) also exhibited prognostic relevance. Meanwhile, metabolomic analysis uncovered a combination-specific blockade of mitochondrial fatty acid oxidation, evidenced by L-Carnitine depletion and accumulation of Hexanoyl-L-Carnitine and Oleoyl-L-Carnitine. This work demonstrates the potential combination interaction of Alm and PTX, converging on the suppression of cell cycle and the induction of carnitine metabolism blockage. Our findings provide a profound mechanistic rationale for this combination therapy.

Scientific Reports
Dalian Institute of Chemical Physics (CN), Dalian Medical University (CN), Chinese Academy of Sciences (CN), First Affiliated Hospital of Dalian Medical University (CN)
National Natural Science Foundation of China
Good health and well-being
Lung Cancer Treatments and Mutations
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Identifying potential combinatorial mechanism between paclitaxel and Almonertinib in lung cancer through multi-omics integration — Tingze Feng, Shaojun Pei, et al. · Scientific Reports (2026) | TGRS Research Map | TGRS